Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter
Achieved net product revenues of $19.7 million for the fourth quarter of 2023 representing 35% year on.
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of AcinetobacterAnnounced positive.
Citations 2023 LiveLaw (Del) 917 to 2023 LiveLaw (Del) 1039NOMINAL INDEXPCIT Versus Pepsico India Holding Pvt. Ltd. 2023 LiveLaw (Del) 917 ADITYA N PRASAD v. GOVERNMENT OF NCT OF DELHI & ORS. 2023.
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023
Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial.